Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of “Buy” from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $25.17.

CNTA has been the topic of several research analyst reports. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets lifted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. B. Riley started coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $16.14 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The business’s 50 day simple moving average is $15.48 and its two-hundred day simple moving average is $11.77. The stock has a market capitalization of $1.83 billion, a P/E ratio of -10.35 and a beta of 1.47. Centessa Pharmaceuticals has a one year low of $5.58 and a one year high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Analysts forecast that Centessa Pharmaceuticals will post -1.68 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $15.38, for a total value of $180,591.96. Following the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $15.38, for a total value of $180,591.96. Following the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 325,031 shares of company stock valued at $5,213,043. 11.59% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. First Light Asset Management LLC increased its position in Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after acquiring an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC increased its position in Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after buying an additional 850,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Centessa Pharmaceuticals by 16.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after buying an additional 418,615 shares in the last quarter. Driehaus Capital Management LLC increased its position in Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares in the last quarter. Finally, Farallon Capital Management LLC increased its position in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after buying an additional 1,625,000 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.